Short answer
Autolus Therapeutics plc (AUTL) filed an 8-K current report with the SEC on November 10, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2). Q3 2026 financial results and corporate update announced for quarter ended September 30, 2026.
Autolus Therapeutics plc 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 financial results and corporate update announced for quarter ended September 30, 2026
- Press release furnished as Exhibit 99.1, containing the substantive financial and operational details
Item 7.01 · Regulation FD Disclosure
- Updated corporate presentation accompanies the November 10, 2026 conference call on quarter ended September 30, 2026 results
- Exhibit 99.2 likely contains management’s latest business, pipeline and financial messaging for investor review
Item EX-99.1 · Exhibit EX-99.1
- Q3 AUCATZYL revenue $41.2M, up 95% year over year, validating accelerating demand across treatment centers
- 2026 revenue outlook raised to at least the upper end of $150M, signaling stronger commercial execution
- Gross margin reached 57%, supported by higher volumes and manufacturing efficiency, improving scalability
- Net loss narrowed to $55.1M from $79.1M, while cash and securities totaled $248.4M at September 30
- Cash runway extended into Q2 2028, including $100M from Perceptive’s credit facility, reducing near-term financing risk
Item EX-99.2 · Exhibit EX-99.2
- Q3 2026 net product revenue $41.2M, up 95% versus Q3 2025; 9M revenue $113.1M, up 122%
- 90 U.S. authorized treatment centers, exceeding the 2026 goal of more than 80
- 2026 revenue expected at or above $150M, the upper end of prior guidance
- Gross margin reached 57% in Q3 and 44% year-to-date, signaling improving commercial economics
- Cash, equivalents and marketable securities totaled $248.4M, with funding expected into Q2 2028 including $100M from Perceptive’s credit facility
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Autolus Therapeutics plc 8-K filings
Get the next AUTL 8-K as it lands
Follow AUTL for push alerts, or ask the research agent what this filing means.